March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Adalimumab For Treatment Of Severe Uveitis Associated To Behçet Disease
Author Affiliations & Notes
  • Emanuela Interlandi
    Ophthalmology, "A. Cardarelli" Hospital, Naples, Italy
  • Valentina Di Iorio
    Ophthalmology, "A. Cardarelli" Hospital, Naples, Italy
  • Raffaele Perrotta
    Ophthalmology, "A. Cardarelli" Hospital, Naples, Italy
  • Loredana Latanza
    Ophthalmology, "A. Cardarelli" Hospital, Naples, Italy
  • Footnotes
    Commercial Relationships  Emanuela Interlandi, None; Valentina Di Iorio, None; Raffaele Perrotta, None; Loredana Latanza, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5494. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Emanuela Interlandi, Valentina Di Iorio, Raffaele Perrotta, Loredana Latanza; Adalimumab For Treatment Of Severe Uveitis Associated To Behçet Disease. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5494.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the effectiveness and safety of Adalimumab therapy in patients affected by refractory Behçet-related uveitis

Methods: : Twelve affected patients (22 eyes) were retrospectively analised after an informed consent was obtained from all of them. All patients received 40 mg of Adalimumab subcutaneously, once every 2 weeks, in addition to traditional immunosuppressive therapy; in all cases Adalimumab was administrated since ocular inflammation did not respond to traditional immunosuppressants and eight of them were switched to Adalimumab after failure of Infliximab therapy. The mean follow-up was 19,92 months (±6,92 SD; range:8-34). Main outcome measures included changes of best corrected visual acuity (BCVA), uveitis attacks and daily steroids dose in addition to uveitis remission and occurrence of Adalimumab-related side effects. Pre-Adalimumab period was defined as a span of time, before Adalimumab administration, correspondent to follow-up period for each patient.

Results: : Mean age of patients (11 males and 1 female) was 32,75 years (± 10,63 SD; range: 13-58), while mean uveitis duration was 7,5 years (± 4,46 SD). Seven patients (58%) were positive to HLA-B51 antigen. Ocular involvment resulted bilateral in 83% of cases and mainly consisted in panuveitis (68% of eyes). During Adalimumab therapy all patients but one (91%) achieved uveitis remission associated to a visual acuity improvment, at least in one eye, in all of them. Mean BCVA improved from 0.45 logMAR at baseline to 0.24 logMAR (p = 0.026), during Adalimumab therapy, in the worse eye. In all Adalimumab responders daily steroids were gradually tapered up to suspension in 73% of them. Mean uveitis attacks per patient decreased from 2,18, during pre- Adalimumab period, to 0,18 during Adalimumab therapy (p < 0,001 ). No patient developed related side effects during Adalimumab administration.

Conclusions: : Thus far severe uveitis associated to Behçet Disease represent a serious sight- threatening condition whose prognosis depends on a prompt and adequate treatment. Our results demonstrate Adalimumab to be a very effective and safe option for treatment of patients with severe Behçet uveitis refractory to traditional immunuppressive and Infliximab therapy.

Keywords: uveitis-clinical/animal model • autoimmune disease • clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.